165 related articles for article (PubMed ID: 21845063)
1. Effects of miglitol in platelet-derived microparticle, adiponectin, and selectin level in patients with type 2 diabetes mellitus.
Nomura S; Omoto S; Yokoi T; Fujita S; Ozasa R; Eguchi N; Shouzu A
Int J Gen Med; 2011; 4():539-45. PubMed ID: 21845063
[TBL] [Abstract][Full Text] [Related]
2. Effect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patients.
Shimazu T; Inami N; Satoh D; Kajiura T; Yamada K; Iwasaka T; Nomura S
J Thromb Thrombolysis; 2009 Nov; 28(4):429-35. PubMed ID: 19137265
[TBL] [Abstract][Full Text] [Related]
3. Effects of pitavastatin on plasminogen activator inhibitor-1 in hyperlipidemic patients.
Nomura S; Taniura T; Shouzu A; Omoto S; Inami N; Fujita S; Tamaki T; Yokoi T; Shimizu T; Ito T
Int J Gen Med; 2012; 5():535-40. PubMed ID: 22807641
[TBL] [Abstract][Full Text] [Related]
4. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
[TBL] [Abstract][Full Text] [Related]
5. Correlation and association between plasma platelet-, monocyte- and endothelial cell-derived microparticles in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Shouzu A; Urase F; Maeda Y
Platelets; 2009 Sep; 20(6):406-14. PubMed ID: 19658004
[TBL] [Abstract][Full Text] [Related]
6. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.
Nomura S; Inami N; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Urase F; Maeda Y; Ohtani H; Iwasaka T
Platelets; 2009 Feb; 20(1):16-22. PubMed ID: 19172517
[TBL] [Abstract][Full Text] [Related]
7. Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus.
Omoto S; Taniura T; Nishizawa T; Tamaki T; Shouzu A; Nomura S
Diabetes Metab Syndr Obes; 2015; 8():339-45. PubMed ID: 26251624
[TBL] [Abstract][Full Text] [Related]
8. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Inami N; Tanaka A; Nanba M; Shouda Y; Takahashi N; Kimura Y; Iwasaka T
Thromb Res; 2008; 122(1):39-45. PubMed ID: 17920663
[TBL] [Abstract][Full Text] [Related]
9. Effects of teneligliptin on PDMPs and PAI-1 in patients with diabetes on hemodialysis.
Okuda Y; Omoto S; Taniura T; Shouzu A; Nomura S
Int J Gen Med; 2016; 9():65-71. PubMed ID: 27110135
[TBL] [Abstract][Full Text] [Related]
10. Activated platelet and oxidized LDL induce endothelial membrane vesiculation: clinical significance of endothelial cell-derived microparticles in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T; Fukuhara S
Clin Appl Thromb Hemost; 2004 Jul; 10(3):205-15. PubMed ID: 15247977
[TBL] [Abstract][Full Text] [Related]
11. 5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Iwasaka T
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):423-8. PubMed ID: 16093733
[TBL] [Abstract][Full Text] [Related]
12. Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Nomura S; Takahashi N; Inami N; Kajiura T; Yamada K; Nakamori H; Tsuda N
Atherosclerosis; 2004 Jun; 174(2):329-35. PubMed ID: 15136063
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD40 ligand, platelet surface CD40 ligand, and total platelet CD40 ligand in atrial fibrillation: relationship to soluble P-selectin, stroke risk factors, and risk factor intervention.
Choudhury A; Chung I; Panja N; Patel J; Lip GYH
Chest; 2008 Sep; 134(3):574-581. PubMed ID: 18641098
[TBL] [Abstract][Full Text] [Related]
14. Adiponectin diminishes platelet aggregation and sCD40L release. Potential role in the metabolic syndrome.
Restituto P; Colina I; Varo JJ; Varo N
Am J Physiol Endocrinol Metab; 2010 May; 298(5):E1072-7. PubMed ID: 20197504
[TBL] [Abstract][Full Text] [Related]
15. Effects of efonidipine on platelet and monocyte activation markers in hypertensive patients with and without type 2 diabetes mellitus.
Nomura S; Kanazawa S; Fukuhara S
J Hum Hypertens; 2002 Aug; 16(8):539-47. PubMed ID: 12149659
[TBL] [Abstract][Full Text] [Related]
16. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus.
Yokoyama H; Kannno S; Ishimura I; Node K
Metabolism; 2007 Nov; 56(11):1458-63. PubMed ID: 17950094
[TBL] [Abstract][Full Text] [Related]
17. Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels.
Tan KT; Tayebjee MH; Lim HS; Lip GY
Diabet Med; 2005 Dec; 22(12):1657-62. PubMed ID: 16401308
[TBL] [Abstract][Full Text] [Related]
18. Losartan and simvastatin inhibit platelet activation in hypertensive patients.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
J Thromb Thrombolysis; 2004 Dec; 18(3):177-85. PubMed ID: 15815879
[TBL] [Abstract][Full Text] [Related]
19. Detection of monocyte-derived microparticles in patients with Type II diabetes mellitus.
Omoto S; Nomura S; Shouzu A; Nishikawa M; Fukuhara S; Iwasaka T
Diabetologia; 2002 Apr; 45(4):550-5. PubMed ID: 12032632
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on soluble CD14, CD40 Ligand, sE- and sP-selectins and MCP-1 in patients with type 2 diabetes mellitus: relationship to cholesterol turnover.
Bláha V; Andrýs C; Smahelová A; Knízek J; Hyspler R; Solichová D; Bláha M; Zadák Z
Pharmacol Res; 2006 Dec; 54(6):421-8. PubMed ID: 17011788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
